featured
Complete Response Rate in Cutaneous Metastatic Melanoma Treated With Intralesional IL-2, Imiquimod, and Topical Retinoid Combination Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
100% Complete Response Rate in Patients With Cutaneous Metastatic Melanoma Treated With Intralesional Interleukin (IL)-2, Imiquimod, and Topical Retinoid Combination Therapy: Results of a Case Series
J Am Acad Dermatol 2015 Aug 07;[EPub Ahead of Print], VY Shi, K Tran, F Patel, J Leventhal, T Konia, MA Fung, R Wilken, MS Garcia, SD Fitzmaurice, J Joo, AM Monjazeb, BA Burrall, B King, S Martinez, SD Christensen, E MaverakisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.